Pfizer Escalates Legal Battle with Novo Nordisk Over $9 Billion Metsera Bid
Pfizer has launched two lawsuits against Novo Nordisk, alleging the Danish pharmaceutical giant's $9 billion offer for Metsera is a tactical move to stifle competition rather than facilitate a deal. The legal filings highlight a stark contrast in proposed timelines—Novo's 30-month closing period versus Pfizer's nine-month framework—which Pfizer argues WOULD deliberately delay Metsera's obesity drug development.
The biotech's board declared Novo's bid superior following a shareholder-driven restructuring, forcing Pfizer to submit a counteroffer by Tuesday. Metsera dismissed Pfizer's litigation as a price-suppression tactic, labeling the antitrust claims as baseless. A Delaware court will hear the case as the bidding war intensifies for the developer of monthly injectable weight-loss treatments.
